back research grants Moorfields UCL Institute of Opthalmology Jonathon Ross Grant Award Video
See UCL Press Release July 2005 Patron Penny Lancaster and Charity Chair Lorraine Thomas present a cheque to Dr Tim Levine for Cataract Research.
Penny
Lancaster, Patron of the Lowe Syndrome Trust presents research grant to the
Institute of Ophthalmology, London
Penny
Lancaster, met Dr
Ms Lancaster was delighted to hand over a cheque for £50,000 to Dr Levine,
which will fund a three year research project entitled “The Cell Biology of
the Effects of Lowe Syndrome in the Eye”.
Lowe Syndrome is a rare incurable disorder that affects only boys and produces
congenital cataracts in the lens of both eyes,
muscle weakness, weak bones, kidney and brain development problems. Sadly life
expectancy is short.
The disease was first recognised in 1952 by Dr Charles Lowe, and is caused by a
gene mutation which makes a defective version of an enzyme named OCRL1, which is
needed for normal function of tissues like the lens, brain and kidney, although
the reasons for this are still quite unclear.
The Lowe Syndrome Trust was set up by Lorraine Thomas as a voluntary charity in
June 2000 when her son, Oscar (then aged 5), was diagnosed with the disease.
Mrs Thomas, chair of the Trust says: "We were
devastated when Oscar was diagnosed with the syndrome at the age of 5. All of
the children are partially sighted or blind due to cataracts and some never ever
walk. Even Lowe children (boys only) who are doing quite well with the disease,
sadly deteriorate with the condition and most die in their teens. I am so
grateful for the research being carried out at the
The Lowe Syndrome Trust (a small voluntary
charity), is delighted to announce an award of £50,000 to Dr T Levine,
Lecturer in Cell Biology, Institute of Ophthalmology, Moorfields, London for a
Lowe Syndrome research project entitled “Cell Biological Analysis OCRL1
in human lens epithelial cells.
This will be the first research of
its kind looking at how Lowe syndrome
causes cataracts leading to blindness.
Quote from Moorfields Childrens Eye Hospital:
"You cannot sit here, week after week, seeing children without wanting to improve the chances of saving their sight. I get frustrated, not because we cannot find answers, but because I know we will. But I want those treatments now. I know we could change the destiny of many more children here and around the world."
1. Levine T.P. and Munro S. (2001) Dual targeting of Osh1p, a yeast homologue of oxysterol-binding protein, to both the Golgi and the nucleus-vacuole junction. Mol Biol Cell 12:1633-1644. abstract
2. Levine T.P. and Munro S. (2002) Targeting of Golgi-specific pleckstrin homology domains involves both PtdIns 4-kinase-dependent, and independent, components Current Biology 12:695-704. abstract
3. Loewen C.J.R., Roy A. and Levine T.P. (2003) A conserved ER targeting motif in three families of lipid binding proteins and in Opi1p binds VAP. EMBO J 22:2025-2035. abstract
4. Loewen C.J.R., Gaspar, M.G., Jesch S.A. , Delon C., Ktistakis N.T., Henry S.A. and Levine T.P. (2004) Phospholipid metabolism in yeast is regulated by Opi1p binding to phosphatidic acid. Science 304:1644-1647. abstract
5. Roy, A. and Levine T.P. (2004) Altered intracellular distribution of PtdIns 4-phosphate detected using the pleckstrin homology domain of Osh2p. J. Biol. Chem. M401583200. abstract
6. Levine T.P. (2004) Membrane contact sites, a network for short-range intracellular communication. Trends in Cell Biology 9:483-490. abstract
Layman's Summary 2006
Previous studies have shown that cells lacking the Lowe Syndrome protein OCRL1 are altered, but the differences have been hard to trace in detail. One thing that has been known for some time is that the levels of a highly active molecule called PIP2 rise, however it has not been shown previously where the PIP2 is. Normally PIP2 is on the external (plasma) membrane of cells, and this might be where the extra molecules also build-up. Alternatively, the extra PIP2 might be on internal membranes inside cells. As part of an ongoing project to look at how lack of OCRL1 affects the development of lens cells, we have developed a technique that detects some of this PIP2 for the first time in the internal parts of living cells. Our next goal is to apply this to lens cells.